StockGuide AI - Assistent für Marktrecherche

Analysten von UBS senkten das Kursziel für Zealand Pharma (ZEAL) auf 540 dänische Kronen aufgrund von Bedenken hinsichtlich der Verträglichkeit von survodutide

06/18/2026, 10:36 PM business rating_drop Analysts: analysts, UBS biotech

Die Aktien von Zealand Pharma haben nach enttäuschenden Daten zu ihrem Gewichtsverlustmedikament survodutide erhebliche Rückgänge verzeichnet, was die Analysten dazu veranlasste, die Verkaufsprognosen zu senken und den Fokus auf das andere Medikament petrelintide zu richten, das bessere Perspektiven im Markt für Fettleibigkeit bieten könnte.

JPMorgan-Analysten heben die Wiedereröffnung des Biotech-IPO-Marktes hervor, während die M&A-Aktivitäten der großen Pharmaunternehmen anhalten

06/15/2026, 10:36 PM business review Analysts: analysts, JPMorgan biotech healthcare

Der Biotech-Sektor erlebt eine Wiederbelebung der Aktivitäten auf dem öffentlichen Markt, doch viele führende Unternehmen ziehen möglicherweise eine Übernahme durch größere Pharmafirmen einer Börseneinführung (IPO) vor. Dieser Trend spiegelt ein selektives Investitionsklima und einen strategischen Wandel in der Herangehensweise der Biotech-Firmen an Wachstum und Finanzierung wider.

Biotech M&A Set for Strongest Year Since Pre-Pandemic as Deal Value Reaches $106 Billion in 2026

06/03/2026, 11:30 PM business review biotech healthcare

The biopharma sector is experiencing a significant surge in mergers and acquisitions, with 2026 poised to become the strongest year since before the pandemic, driven by patent expirations and a favorable market environment.

Abivax (ABVX) Shares Plunge Over 30% Following Update on Bowel Disease Drug Trial

06/02/2026, 12:31 AM stock_drop biotech

Abivax is strategically planning to raise funds following the release of crucial trial data, indicating its intent to remain independent amid ongoing takeover speculation, which has significantly influenced its stock performance.

Innovent Biologics (1801.HK) Shares Surge 10% Following $10.5 Billion Partnership with Pfizer

05/28/2026, 08:32 PM announcement biotech

Innovent Biologics has entered a strategic partnership with Pfizer, which is expected to enhance its oncology drug development capabilities.

Analysts BTIG initiate coverage of Absci Corporation (ABSI) with a buy rating and $9 price target, citing potential for ABS-201 in hair loss treatment

05/28/2026, 07:33 AM investing rating_growth Analysts: analysts, BTIG biotech

Absci Corporation's innovative hair loss treatment, ABS-201, has garnered a buy rating from BTIG, with a projected peak sales potential of $2.2 billion, indicating significant market opportunity in a largely underserved sector.

Analysts Goldman Sachs initiate coverage of Hemab Therapeutics (HEMA) with Buy rating and $36 target price, citing potential for unique bleeding disorder treatment

05/26/2026, 07:32 AM investing rating_growth Analysts: analysts, Goldman Sachs biotech

Hemab Therapeutics is positioned for significant growth following its IPO, driven by its development of unique treatments for rare bleeding disorders, as highlighted by Goldman Sachs' bullish outlook.

U.S. Promotes AI Technology in Asia Following Trump-Xi Meeting

05/22/2026, 05:34 AM business announcement ai biotech

The U.S. is intensifying efforts to promote American technology, particularly in artificial intelligence, in Asia amid competition with China, which is developing its own alternatives. This strategic push follows a recent meeting between Presidents Trump and Xi, highlighting the importance of U.S. tech in the region.

Biotech and Real Estate Sectors Show Mixed Performance Ahead of Key Oncology Meeting

05/21/2026, 04:32 PM investing review biotech real_estate

The upcoming meeting of the American Society of Clinical Oncology is poised to influence biotech stocks, which have shown significant gains over the past year despite recent fluctuations. Additionally, a substantial government investment in quantum computing has sparked notable stock increases in that sector.

Topic: biotech